Pancreatic Cancer Translational
The overall aim of our group is to therapeutically target tumour cells and stromal pancreatic stellate cells (PSCs) which both contribute to tumour progression and chemoresistance in pancreatic cancer. Patients with pancreatic cancer have a dismal prognosis, with the best treatments currently only increasing survival by 6-12 weeks.
Our research is at the forefront in identifying novel targets to treat pancreatic cancer and using relevant in vitro and in vivo models to study this disease. Current research focuses on identifying novel therapeutic approaches for pancreatic cancer including targeting the extensive scarring (fibrosis) which we have shown enhances pancreatic cancer progression.
To address our aims we utilise a novel nanotechnology siRNA approach to silence key genes involved in tumour progression and chemoresistance. Success with competitive grant funding (NH&MRC, NSW Cancer Council, Cancer Institute NSW, Cure Cancer Australia, Ramaciotti) attests to the productivity and national and international standing of the Group.